Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Sanofi’s tolebrutinib has been shown to delay disability progression in multiple sclerosis (MS) patients, according to phase ...

Tolebrutinib represents Sanofi's commitment to developing innovative treatments that address the underlying causes of neurological diseases and potentially transform the treatment landscape.

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive ...

At the American Academy of Neurology (AAN) 2025 Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing secondary progressive multiple ...

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in ...

The New England Journal of Medicine published results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability ...

Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...